These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15140336)

  • 1. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
    Eisman JA; Rizzoli R; Roman-Ivorra J; Lipschitz S; Verbruggen N; Gaines KA; Melton ME
    Curr Med Res Opin; 2004 May; 20(5):699-705. PubMed ID: 15140336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
    Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A
    Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis.
    Cryer B; Binkley N; Simonelli C; Lewiecki EM; Lanza F; Chen E; Petruschke RA; Mullen C; de Papp AE
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):127-36. PubMed ID: 16257815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
    Bauer DC; Black D; Ensrud K; Thompson D; Hochberg M; Nevitt M; Musliner T; Freedholm D
    Arch Intern Med; 2000 Feb; 160(4):517-25. PubMed ID: 10695692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
    Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
    Cryer B; Miller P; Petruschke RA; Chen E; Geba GP; Papp AE
    Aliment Pharmacol Ther; 2005 Mar; 21(5):599-607. PubMed ID: 15740544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
    Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
    Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms.
    Miller PD; Woodson G; Licata AA; Ettinger MP; Mako B; Smith ME; Wang L; Yates SJ; Melton ME; Palmisano JJ
    Clin Ther; 2000 Dec; 22(12):1433-42. PubMed ID: 11192135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.